PHASE 1/2 STUDY: FRONTLINE BRENTUXIMAB VEDOTIN plus AVD IN PEDIATRIC PTS WITH ADVANCED HODGKIN LYMPHOMA

被引：0
|
作者：
Franklin, Anna [1 ]
Zecca, Marco [1 ]
Fagioli, Franca [1 ]
Luisi, Flavio Augusto [1 ]
Song, Gregory [1 ]
Suri, Ajit [1 ]
Leonard, E. Jane [1 ]
Locatelli, Franco [1 ]
机构：
[1] Childrens Hosp Colorado, Aurora, CO USA
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
106
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Brentuximab Vedotin Combined with ABVD or AVD for Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma: Long Term Outcomes
    Connors, Joseph M.
    Ansell, Stephen
    Park, Steven I.
    Fanale, Michelle A.
    Younes, Anas
    BLOOD, 2014, 124 (21)
  • [32] Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A plus AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL).
    Younes, Anas
    Radford, John
    Ansell, Stephen Maxted
    Gallamini, Andrea
    Kim, Wom Seog
    Feldman, Tatyana A.
    Hamadani, Mehdi
    Chung, Jeanenne
    Wang, Jingyuan
    Huebner, Dirk
    Connors, Joseph M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Brentuximab Vedotin Plus Bendamustine Is an Effective Salvage Regimen for Pediatric Patients with Relapsed Hodgkin Lymphoma
    Gulati, Nitya
    Boulad, Farid
    Cancio, Maria I.
    Curran, Kevin J.
    Jackson, Carolyn
    Kernan, Nancy
    Kung, Andrew L.
    O'Reilly, Richard
    Prockop, Susan
    Ramaswamy, Kavitha
    Scaradavou, Andromachi
    Spitzer, Barbara
    Shukla, Neerav
    Steinherz, Peter G.
    Forlenza, Christopher
    BLOOD, 2017, 130
  • [34] Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A plus AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study
    Ansell, Stephen Maxted
    Younes, Anas
    Connors, Joseph M.
    Gallamini, Andrea
    Kim, Won Seog
    Friedberg, Jonathan W.
    Feldman, Tatyana A.
    Collins, Graham
    Bartlett, Nancy
    Wang, Jingyuan
    Brady, Kelly
    Sachs, Jessica
    Huebner, Dirk
    Hunder, Naomi N. H.
    Radford, John
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
    Gopal, Ajay K.
    Chen, Robert
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Savage, Kerry J.
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Chi, Xuedong
    Sievers, Eric L.
    Younes, Anas
    BLOOD, 2015, 125 (08) : 1236 - 1243
  • [36] Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma
    Abramson, Jeremy S.
    Stuver, Robert
    Herrera, Alex
    Patterson, Emily
    Wen, Yi-Ping
    Moskowitz, Alison
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 204
  • [37] Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma
    Delea, Thomas E.
    Sharma, Arati
    Grossman, Aaron
    Eichten, Caitlin
    Fenton, Keenan
    Josephson, Neil
    Richhariya, Akshara
    Moskowitz, Alison J.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (02) : 117 - 130
  • [38] Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
    Younes, Anas
    Connors, Joseph M.
    Park, Steven I.
    Fanale, Michelle
    O'Meara, Megan M.
    Hunder, Naomi N.
    Huebner, Dirk
    Ansell, Stephen M.
    LANCET ONCOLOGY, 2013, 14 (13): : 1348 - 1356
  • [39] BRENTUXIMAB VEDOTIN MAY CUT RADIATION USE IN PEDIATRIC HODGKIN LYMPHOMA
    不详
    CANCER DISCOVERY, 2021, 11 (06) : 1318 - 1318
  • [40] Brentuximab Vedotin: First-line Agent for Advanced Hodgkin Lymphoma
    Ca, Huynh
    Yamamoto, Kenneth
    Yang, Li-Xi
    Weber, Robert
    ANTICANCER RESEARCH, 2013, 33 (09) : 3879 - 3885
12345